Trial Profile

Endovascular Treatment of Patients with Critical Limb Ischemia - GIKEI

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fondaparinux sodium (Primary) ; Aspirin; Clopidogrel
Indications Chronic limb-threatening ischemia; Peripheral arterial disorders; Restenosis
Focus Therapeutic Use
Acronyms GIKEI

Most Recent Events

18 Mar 2020 New trial record
13 Mar 2020 Results assessing Clinical safety of low-dose anticoagulation with fondaparinux in patients undergoing peripheral endovascular treatment due to critical limb-threatening ischaemia, published in the Acta Cardiologica

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com